Apidra - Side Effects insulin glulisine

Side Effects for APIDRA (insulin glulisine injection, solution) are also known as adverse reactions. Below is a summary of known side effects for Apidra.

Adverse Reactions

The following adverse reactions are discussed elsewhere:

clinical trials experience

Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.

The frequencies of adverse drug reactions during APIDRA clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in the tables below.

Table 1: Adverse Reactions Occurring ≥5% in Pooled Studies of Adults with Type 1 Diabetes
APIDRA, %
(n=950)
All Comparators
Insulin lispro, regular human insulin, insulin aspart

, %
(n=641)

Nasopharyngitis 10.6 12.9
Hypoglycemia
Only severe symptomatic hypoglycemia
6.8 6.7
Upper respiratory tract infection 6.6 5.6
Influenza 4.0 5.0
Table 2: Adverse Reactions Occurring ≥5% in Pooled Studies of Adults with Type 2 Diabetes
APIDRA, %
(n=883)
Regular Human Insulin, %
(n=883)
Upper respiratory tract infection 10.5 7.7
Nasopharyngitis 7.6 8.2
Edema peripheral 7.5 7.8
Influenza 6.2 4.2
Arthralgia 5.9 6.3
Hypertension 3.9 5.3

Pediatrics

Table 3 summarizes the adverse reactions occurring with frequency higher than 5% in a clinical study in pediatric patients with type 1 diabetes treated with APIDRA (n=277) or insulin lispro (n=295).

Table 3: Adverse Reactions Occurring ≥5% in Pediatric Patients with Type 1 Diabetes
APIDRA, %
(n=277)
Lispro, %
(n=295)
Nasopharyngitis 9.0 9.5
Upper respiratory tract infection 8.3 10.8
Headache 6.9 11.2
Hypoglycemic seizure 6.1 4.7

Severe Symptomatic Hypoglycemia

Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including APIDRA. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for APIDRA with the incidence of hypoglycemia for other products may be misleading and also, may not be representative of hypoglycemia rates that occur in clinical practice. The rates and incidence of severe symptomatic hypoglycemia, defined as hypoglycemia requiring intervention from a third party are presented in Table 4. In the clinical trials, children and adolescents with type 1 diabetes had a higher incidence of severe symptomatic hypoglycemia in the two treatment groups compared to adults with type 1 diabetes (see Table 4) [see Clinical Studies (14)].

Table 4: Severe Symptomatic Hypoglycemia
Severe symptomatic hypoglycemia defined as a hypoglycemic event requiring the assistance of another person that met one of the following criteria:
the event was associated with a whole blood referenced blood glucose <36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, intravenous glucose or glucagon administration.
Type 1 Diabetes
Adults
12 weeks with insulin glargine
Type 1 Diabetes
Adults
26 weeks with insulin glargine
Type 2 Diabetes
Adults
26 weeks with NPH human insulin
Type 1 Diabetes
Pediatrics
26 weeks
APIDRA
Pre meal
APIDRA
Post meal
Regular Human Insulin APIDRA Insulin Lispro APIDRA Regular Human Insulin APIDRA Insulin Lispro
Events per month per patient 0.05 0.05 0.13 0.02 0.02 0.00 0.00 0.09 0.08
Percent of patients (n/total N) 8.4%
(24/286)
8.4%
(25/296)
10.1%
(28/278)
4.8%
(16/339)
4.0%
(13/333)
1.4%
(6/416)
1.2%
(5/420)
16.2%
(45/277)
19.3%
(57/295)

Adverse Reactions with Continuous Subcutaneous Insulin Infusion (CSII)

In a 12-week randomized study in patients with type 1 diabetes (n=59), the rates of catheter occlusions and infusion site reactions were similar for APIDRA and insulin aspart–treated patients (see Table 5).

Table 5: Catheter Occlusions and Infusion Site Reactions.
APIDRA
(n=29)
Insulin Aspart
(n=30)
Catheter occlusions/month 0.08 0.15
Infusion site reactions 10.3% (3/29) 13.3% (4/30)

Allergic Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with any insulin, including APIDRA. Generalized allergy to insulin may cause whole body rash (including pruritus), dyspnea, wheezing, hypotension, tachycardia, or diaphoresis.

In controlled clinical trials up to 12 months duration, potential systemic allergic reactions were reported in 79 of 1833 patients (4.3%) who received APIDRA and 58 of 1524 patients (3.8%) who received the comparator short-acting insulins. During these trials, treatment with APIDRA was permanently discontinued in 1 of 1833 patients due to a potential systemic allergic reaction.

Injection Site Reactions

As with any insulin therapy, patients taking APIDRA may experience redness, swelling, or itching at the site of injection. These minor reactions usually resolve in a few days to a few weeks, but in some occasions may require discontinuation of APIDRA. In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique.

Insulin Initiation and Intensification of Glucose Control

Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.

Lipodystrophy

Long-term use of insulin, including APIDRA, can cause lipodystrophy at the site of repeated insulin injections or infusion. Lipodystrophy includes lipohypertrophy (thickening of adipose tissue) and lipoatrophy (thinning of adipose tissue), and may affect insulin absorption [see Dosage and Administration (2.2)].

Peripheral Edema

Insulin, including APIDRA, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Weight Gain

Weight gain can occur with insulin therapy, including APIDRA, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.

immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to APIDRA in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In a study in patients with type 1 diabetes (n=333), the concentrations of insulin antibodies that react with both human insulin and insulin glulisine (cross-reactive insulin antibodies) remained near baseline during the first 6 months of the study in the patients treated with APIDRA. A decrease in antibody concentration was observed during the following 6 months of the study. In a study in patients with type 2 diabetes (n=411), a similar increase in cross-reactive insulin antibody concentration was observed in the patients treated with APIDRA and in the patients treated with human insulin during the first 9 months of the study. Thereafter the concentration of antibodies decreased in the APIDRA patients and remained stable in the human insulin patients. There was no correlation between cross-reactive insulin antibody concentration and changes in HbA1c, insulin doses, or incidence of hypoglycemia. APIDRA did not elicit a significant antibody response in a study of children and adolescents with type 1 diabetes.

postmarketing experience

The following adverse reactions have been identified during postapproval use of APIDRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.

Medication errors have been reported in which other insulins, particularly long-acting insulins, have been accidentally administered instead of APIDRA.

This drug label information is as submitted to the Food and Drug Administration (FDA) and is intended for informational purposes only. If you think you may have a medical emergency, immediately call your doctor or dial 911. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Search Drugs and Medication

Or Browse by Name

Top Reads
  • Learn about drugs going generic in 2021 and how you may be able to save money on common prescription medication by switching to drugs coming off-patent.
    November 20, 2019
  • To make sure your medicines work as they should, here are some of the most common food-and-drug combinations to avoid.
    October 22, 2015
  • Get a list of the top 50 prescription drugs out of the annual 3 billion prescriptions filled at U.S. pharmacies.
    September 5, 2019
  • While medications are extremely useful in treating various diseases and conditions, sometimes they can cause unwanted side effects—one of which can be sexual dysfunction. Talk to your doctor if you’re taking any of these common medications that affect sex drive.
    September 23, 2016
  • Here’s a look at the most commonly abused prescription drugs.
    October 30, 2014

Love the Doctor Who Prescribed This Medication?

Top Drugs
  • Digestive health drugs manage diseases, disorders and conditions of the gastrointesinal system. They provide treatment and symptom relief for functional and structural problems with digestive organs.
  • Antibiotic, antifungal and antiviral drugs treat infectious diseases. They kill or stop the growth of microorganisms, including bacteria, fungi and viruses.
  • Birth control medications are a form of contraception. They contain either a combination of estrogen and progestin or progestin alone. There are several forms of these hormones, but most combination products contain estrogen, ethinyl estradiol, and a progestin. They work by preventing ovulation and inhibiting fertilization and implantation.
  • Mental health drugs treat conditions that affect emotional, psychological and social well-being. Doctors frequently use mental health drugs in combination with various forms of therapy to help people manage these conditions.